

## CS Pharmaceuticals Announces US patent granted

*- Protects CS Pharmaceuticals' CSP-270 product until 2038 -*

**LONDON, England and BEIJING and SHANGHAI, China – September 20<sup>th</sup> 2023 –**

CS Pharmaceuticals Ltd. (CSP), a British speciality company focused on first- and best-in-class speciality and ocular therapeutics in China, are pleased to announce the granting of US patent 11,759,472 B2 titled “Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface. The patent provides protection for CSP’s global product CSP-270 in the US market place until 2038, with potential for patent term extension to 2043.

“We are thrilled at the granting of this US patent following the outcome of a successful appeal to the US Patent Office. The granted patent protects our global asset CSP-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops. CSP-270 has a set of unique product features and strong phase 2 clinical data generated in a population with Meibomian gland dysfunction. We strongly believe that CSP-270 will provide huge clinical benefits to patients.” said Darren Mercer, Chief Executive of CSP.

CSP-270 is highly differentiated from typical topical ocular corticosteroid drops as it is formulated into a cream that is applied once daily to the eyelid, from where the drug is absorbed into the Meibomian gland, and forms a depot that is delivered to the surface of the eye every time the patient blinks. This results in 10x-100x higher concentration of drug in the ocular tissues compared to drops, and also avoids the problems of drug being lost due to tearing, or patients forgetting to follow the 4x daily dosing instructions which are typical of such products. The CSP-270 product contains a novel selective glucocorticoid receptor agonist that has been exclusively licensed for use in ophthalmology. Phase 2 clinical study results in patients with posterior blepharitis and dry eye disease due to meibomian gland dysfunction show improvements in Visual Analogue Scale for eye discomfort as early as 1 week after starting treatment and statistically significant and clinically meaningful differences from placebo after 3 weeks of treatment. CSP-270 also demonstrated statistically significant changes from baseline in Visual Analogue Scale for Eye Dryness and total Fluorescein Corneal Staining 1 week after starting treatment and statistically significant increased Tear Break Up Time 2 weeks after starting treatment; these improvements continued to increase after 3 weeks treatment.

### **About CS Pharmaceuticals**

CS Pharmaceuticals (CSP) is a British multinational company focused on licensing Chinese commercialisation rights to Western speciality and ophthalmology medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CS Pharmaceuticals is rapidly becoming a ‘go-to’ trusted licensing partner, expanding its portfolio of innovative speciality and ophthalmology assets while making business easier for companies wishing to develop and commercialise their products in China.

**Contacts**

CS Pharmaceuticals

Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691

